Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative
to placebo among approximately 300 hospitalized adult patients who have severe COVID-19. The
study will be a 2 arm double blinded comparison between tocilizumab 8 mg/kg and matching
placebo IV. The dose may be repeated in 8-12 hours if clinical symptoms worsens, (e.g.
increase in oxygen requirements). Participants will be followed for 28 days.